DeepMed Research

The Gynecologic Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1970-01-01

Employees: 11

Market Cap: -

Website: http://www.gog.org

Clinical Trials

Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer

Conditions: Endometrial Cancer

First Posted Date: 2010-05-07

Last Posted Date: 2010-06-22

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 100

Registration Number: NCT01119573

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Carcinoma
Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1

First Posted Date: 2010-05-06

Last Posted Date: 2018-01-11

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 22

Registration Number: NCT01118052

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 8 locations

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

Completed

Conditions: Stage I Uterine Sarcoma
Stage IB Cervical Cancer
Stage II Uterine Corpus Cancer
Stage II Uterine Sarcoma
Stage III Uterine Corpus Cancer
Stage IVA Cervical Cancer
Stage I Uterine Corpus Cancer
Stage III Cervical Cancer
Stage IVB Cervical Cancer
Recurrent Uterine Corpus Carcinoma

Interventions: Other: Medical Chart Review
Other: Questionnaire Administration

First Posted Date: 2010-04-05

Last Posted Date: 2018-04-12

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 778

Registration Number: NCT01098630

Locations: 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
🇺🇸
Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States

and more 164 locations

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Completed

Conditions: Malignant Ovarian Epithelial Tumor
Ovarian Polyembryoma
Stage I Ovarian Cancer
Stage IA Ovarian Cancer
Stage IA Ovarian Germ Cell Tumor
Stage IB Ovarian Germ Cell Tumor
Stage IC Fallopian Tube Cancer
Stage IIC Ovarian Germ Cell Tumor
Stage IIIA Ovarian Cancer
Stage IIIA Primary Peritoneal Cancer

Interventions: Procedure: Cognitive Assessment
Other: Quality-of-Life Assessment

First Posted Date: 2010-03-04

Last Posted Date: 2018-04-12

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 247

Registration Number: NCT01080521

Locations: 🇺🇸
Clements University Hospital, Dallas, Texas, United States
🇺🇸
Marshfield Clinic Cancer Care at Saint Michael's Hospital, Stevens Point, Wisconsin, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 179 locations

Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2010-02-24

Last Posted Date: 2010-02-24

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 513

Registration Number: NCT01074398

Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer

Conditions: Cervical Cancer

First Posted Date: 2010-02-24

Last Posted Date: 2010-02-24

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 84

Registration Number: NCT01074424

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Rilotumumab

First Posted Date: 2009-12-24

Last Posted Date: 2017-09-07

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 31

Registration Number: NCT01039207

Locations: 🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 25 locations

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Recruiting

Conditions: Stage IIIB Ovarian Cancer
Stage IIIA Ovarian Cancer
Stage IIIC Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Other: Laboratory Biomarker Analysis

First Posted Date: 2009-10-23

Last Posted Date: 2017-05-05

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 174

Registration Number: NCT01000259

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Not Applicable

Conditions: Recurrent Ovarian Carcinoma
Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma
Psychological Impact of Cancer

Interventions: Other: Educational Intervention
Other: Communication Intervention
Other: Internet-Based Intervention
Procedure: Psychosocial Assessment and Care
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2009-08-13

Last Posted Date: 2019-03-12

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 485

Registration Number: NCT00958698

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

and more 141 locations

Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer

Not Applicable

Conditions: Lymphedema
Stage IB Cervical Cancer
Stage IVB Vulvar Cancer
Stage IA Cervical Cancer
Stage IA Vulvar Cancer
Stage II Uterine Corpus Cancer
Stage IIA Cervical Cancer
Stage IIIB Vulvar Cancer
Stage IB Vulvar Cancer
Stage IIIA Vulvar Cancer

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Study of High Risk Factors
Procedure: Therapeutic Conventional Surgery
Procedure: Therapeutic Laparoscopic Surgery
Procedure: Therapeutic Lymphadenectomy

First Posted Date: 2009-08-11

Last Posted Date: 2017-05-08

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 1055

Registration Number: NCT00956670

Locations: 🇺🇸
Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States

and more 209 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy